Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis

Michael G. Feely, James Robert O'Dell

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The present review will focus on the role of conventional disease-modifying antirheumatic drugs (DMARDs) in the current management of rheumatoid arthritis (RA). RECENT FINDINGS: Over the past several decades, the treatment of RA has been revolutionized, not only by the development of highly effective biologic agents but also through a better understanding of the critical importance of early DMARD treatment with a goal of remission or low disease activity and of how to effectively and safely use conventional DMARDs, either as monotherapy or in combinations. SUMMARY: Conventional DMARDs have proven efficacy in the management of RA and remain a valid treatment option, either in monotherapy or as a component of combination regimens. Although conventional DMARDs have associated toxicities, these are distinct from those of the biologic DMARDs. In addition, conventional DMARDs are much less expensive than biologic DMARDs, and in many cases can be successful in achieving similar control of disease activity. The goal for all patients should be achieving remission, or at least low disease activity, with the most cost-effective therapy possible.

Original languageEnglish (US)
Pages (from-to)316-320
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume22
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
Biological Factors
Therapeutics
Costs and Cost Analysis

Keywords

  • Disease-modifying antirheumatic drugs
  • Hydroxychloroquine
  • Leflunomide, methotrexate
  • Rheumatoid arthritis
  • Sulfasalazine

ASJC Scopus subject areas

  • Rheumatology

Cite this

Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. / Feely, Michael G.; O'Dell, James Robert.

In: Current Opinion in Rheumatology, Vol. 22, No. 3, 05.2010, p. 316-320.

Research output: Contribution to journalReview article

@article{79728e31ac94486598a132342e824bc5,
title = "Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis",
abstract = "PURPOSE OF REVIEW: The present review will focus on the role of conventional disease-modifying antirheumatic drugs (DMARDs) in the current management of rheumatoid arthritis (RA). RECENT FINDINGS: Over the past several decades, the treatment of RA has been revolutionized, not only by the development of highly effective biologic agents but also through a better understanding of the critical importance of early DMARD treatment with a goal of remission or low disease activity and of how to effectively and safely use conventional DMARDs, either as monotherapy or in combinations. SUMMARY: Conventional DMARDs have proven efficacy in the management of RA and remain a valid treatment option, either in monotherapy or as a component of combination regimens. Although conventional DMARDs have associated toxicities, these are distinct from those of the biologic DMARDs. In addition, conventional DMARDs are much less expensive than biologic DMARDs, and in many cases can be successful in achieving similar control of disease activity. The goal for all patients should be achieving remission, or at least low disease activity, with the most cost-effective therapy possible.",
keywords = "Disease-modifying antirheumatic drugs, Hydroxychloroquine, Leflunomide, methotrexate, Rheumatoid arthritis, Sulfasalazine",
author = "Feely, {Michael G.} and O'Dell, {James Robert}",
year = "2010",
month = "5",
doi = "10.1097/BOR.0b013e3283383f87",
language = "English (US)",
volume = "22",
pages = "316--320",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis

AU - Feely, Michael G.

AU - O'Dell, James Robert

PY - 2010/5

Y1 - 2010/5

N2 - PURPOSE OF REVIEW: The present review will focus on the role of conventional disease-modifying antirheumatic drugs (DMARDs) in the current management of rheumatoid arthritis (RA). RECENT FINDINGS: Over the past several decades, the treatment of RA has been revolutionized, not only by the development of highly effective biologic agents but also through a better understanding of the critical importance of early DMARD treatment with a goal of remission or low disease activity and of how to effectively and safely use conventional DMARDs, either as monotherapy or in combinations. SUMMARY: Conventional DMARDs have proven efficacy in the management of RA and remain a valid treatment option, either in monotherapy or as a component of combination regimens. Although conventional DMARDs have associated toxicities, these are distinct from those of the biologic DMARDs. In addition, conventional DMARDs are much less expensive than biologic DMARDs, and in many cases can be successful in achieving similar control of disease activity. The goal for all patients should be achieving remission, or at least low disease activity, with the most cost-effective therapy possible.

AB - PURPOSE OF REVIEW: The present review will focus on the role of conventional disease-modifying antirheumatic drugs (DMARDs) in the current management of rheumatoid arthritis (RA). RECENT FINDINGS: Over the past several decades, the treatment of RA has been revolutionized, not only by the development of highly effective biologic agents but also through a better understanding of the critical importance of early DMARD treatment with a goal of remission or low disease activity and of how to effectively and safely use conventional DMARDs, either as monotherapy or in combinations. SUMMARY: Conventional DMARDs have proven efficacy in the management of RA and remain a valid treatment option, either in monotherapy or as a component of combination regimens. Although conventional DMARDs have associated toxicities, these are distinct from those of the biologic DMARDs. In addition, conventional DMARDs are much less expensive than biologic DMARDs, and in many cases can be successful in achieving similar control of disease activity. The goal for all patients should be achieving remission, or at least low disease activity, with the most cost-effective therapy possible.

KW - Disease-modifying antirheumatic drugs

KW - Hydroxychloroquine

KW - Leflunomide, methotrexate

KW - Rheumatoid arthritis

KW - Sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=77950294232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950294232&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e3283383f87

DO - 10.1097/BOR.0b013e3283383f87

M3 - Review article

C2 - 20190639

AN - SCOPUS:77950294232

VL - 22

SP - 316

EP - 320

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -